Real-world treatment patterns and health care resource use for patients with myelofibrosis: results from the METER study

Abstract: Myelofibrosis (MF), a myeloproliferative neoplasm, was most commonly treated with hydroxyurea (HU) before approval of ruxolitinib (RUX), now the standard of care. Factors that influence real-world MF treatment patterns are not well understood. The METER study was a multi-country, retrospec...

全面介紹

書目詳細資料

Principais autores:	Vikas Gupta, Ciprian Tomuleasa, Gilberto Israel Barranco Lampón, Hsin-An Hou, Grzegorz Helbig, Pankit Vachhani, Argiris Symeonidis, Ibrahim Haznedaroglu, Kenny Galvez, Fernando Tatsch, Avijeet S. Chopra, Meng Zhang, Tamas Vizkelety, Bryan Murray, David M. Ross
格式:	Artigo
語言:	Inglês
出版:	Elsevier 2025-03-01
叢編:	Blood Advances
在線閱讀:	http://www.sciencedirect.com/science/article/pii/S247395292400750X
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!